Platform

Based on the evolving scientific understanding of immune dysfunction and the tumor microenvironment, TriSalus is taking an integrated approach to treating liver and pancreatic tumors.

Video Thumbnail with text: Prologue
Play Video about Video Title Slide: Prologue

TriSalus takes an integrated approach tailored to the target organ and disease biology, with the goal to overcome two critical barriers: immunosuppression and delivery.

Watch to learn how our platform approach applies to the treatment of liver tumors.

0:39 min

Share video

Our Platform

The TriSalus™ platform has the potential to overcome the barriers that limit treatment success for liver and pancreatic tumors. Through our work, we aim to enable more patients to benefit from checkpoint inhibitors and other immunotherapeutic agents. To learn more about our current work, see our pipeline page.

Illustration overview of TriSalus’ platform. The indications TriSalus focuses on are the liver and pancreas, their location is shown in an elderly man. TriSalus’ approach is based on the scientific understanding of the tumor biology, focused on two significant barriers to deliver: immunosuppression and intratumoral pressure. TriSalus’ integrated approach combines immunomodulatory medicines, such as their therapeutic candidate SD-101, and proprietary delivery technology catered to the organ. TriSalus is currently implementing this approach in their clinical pipeline.
Illustration overview of TriSalus’ platform. The indications TriSalus focuses on are the liver and pancreas, their location is shown in an elderly man. TriSalus’ approach is based on the scientific understanding of the tumor biology, focused on two significant barriers to deliver: immunosuppression and intratumoral pressure. TriSalus’ integrated approach combines immunomodulatory medicines, such as their therapeutic candidate SD-101, and proprietary delivery technology catered to the organ. TriSalus is currently implementing this approach in their clinical pipeline.

1. Indications with Dysfunctional Immune Environments

Illustration of the liver and the pancreas, two organs in which a dysfunctional immune system plays a role in tumor progression.

TriSalus is focused on indications that are characterized by immune dysfunction at an organ and tumor level, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), pancreatic ductal adenocarcinoma (PDAC), PDAC with liver metastases, uveal melanoma with liver metastases, and colorectal cancer with liver metastases.

Illustration of the liver and the pancreas, two organs in which a dysfunctional immune system plays a role in tumor progression.

2. Understanding Immune Dysfunction and the Tumor Microenvironment

Illustration of the location of the liver and pancreas in an elderly man, with a callout bubble to show the tumor microenvironment, including immunosuppression and intratumoral pressure.

We believe that poor outcomes in liver and pancreatic cancers are due to immune dysfunction specific to the liver and the tumor microenvironments in the liver and pancreas, as well as high intratumoral pressure which limits delivery efficacy. These barriers play a key role in preventing consistent and durable treatment responses.

At TriSalus, we are dedicated to researching these organ-specific issues to develop better treatments.

Illustration of the location of the liver and pancreas in an elderly man, with a callout bubble to show the tumor microenvironment, including immunosuppression and intratumoral pressure.
Illustration of different therapies TriSalus is exploring, with a current focus on investigational SD-101, a selective toll-like receptor agonist.

3a. Immunomodulatory Therapies

Illustration of different therapies TriSalus is exploring, with a current focus on investigational SD-101, a selective toll-like receptor agonist.

Our investigational agent SD-101, a selective toll-like receptor agonist, has demonstrated reversal of immunosuppression and promotion of responses to other forms of immunotherapy in early studies.1,2 We are presently developing SD-101 to enable immunotherapy for patients with liver metastases, primary liver tumors and pancreatic cancer. In addition, we intend to in-license or acquire other immuno-oncology products and other tumor-killing agents to combine with SD-101 to further improve patient outcomes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

Illustration of the devices based on TriSalus’ Pressure-enabled Drug Delivery method.

3b. Pressure-Enabled Drug Delivery™ (PEDD™)

Illustration of the devices based on TriSalus’ Pressure-enabled Drug Delivery method.

We are combining SD-101 with our PEDD method to improve intravascular therapeutic delivery by modulating pressure and flow to enhance local drug concentrations in tumors. In preclinical and clinical studies, PEDD has demonstrated increased therapeutic delivery and improved tumor response in the liver across a range of modalities and geographies.3–8

4. Working to Bring New Treatments to Patients

Schematic representation of a clinical pipeline

We are working tirelessly to conduct clinical trials to develop new treatments for patients. Our drive for innovation is fueled by our passion for patients.

Schematic representation of a clinical pipeline

CITATIONS

1. Looi CK, et al. J Exp Clin Cancer Res. 2019;38(1):162.
2. Ribas A, et al. Cancer Discov. 2018;8(10):1250-1257.
3. Titano JJ, et al. Cardiovasc Intervent Radiol. 2019;42(4):560-568.
4. Pasciak AS, et al. J Vasc Interv Radiol. 2015;26(5):660-669.
5. Katz SC, et al. J Immunother Cancer. 2020;8(2):e001097.
6. d’Abadie P, et al. Diagn Interv Radiol. 2021;27(6):768-773.
7. Data on File, Porcine Animal Model, TriSalus Life Sciences®, 2019.
8. Shankara Narayanan JS, et al. Surgery. 2020;168(3):448-456.

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL